Dr. Healy has over 15 years of experience in disease biology, leading independent research efforts in the areas of neuroscience, cardiovascular pathophysiology, oncology and inflammation. From 2001 until 2008, Dr. Healy held positions of increasing responsibility at Momenta Pharmaceuticals and Millennium Pharmaceuticals. Her prior preclinical research in drug discovery and development included significant contributions to target identification, lead optimization, in vivo pharmacology and biomarker discovery for small molecules and biologics. Before taking those positions, Dr. Healy was a faculty member at Boston University School of Medicine, where her research focused on cellular and molecular mechanisms of pulmonary development and disease. Dr. Healy holds patents and has published in peer-reviewed journals on a wide range of topics including biomarkers and the molecular mechanisms of disease. Dr. Healy received her PhD in cellular biology at Tufts University Medical School and completed her postdoctoral training in the molecular biology of the blood vessel wall at the Massachusetts Institute of Technology.
Aileen Healy
Vice President, Research
Seaside Therapeutics
From this contributor
Better biomarkers
New funding will help Seaside Therapeutics, a Massachusetts-based company, develop biomarkers to track the success of treatments for autism, says Aileen Healy.
Explore more from The Transmitter
Connectomics 2.0: Simulating the brain
With a complete fly connectome in hand, researchers are taking the next step to model how brain circuits fuel function.
Connectomics 2.0: Simulating the brain
With a complete fly connectome in hand, researchers are taking the next step to model how brain circuits fuel function.
CDC autism prevalence numbers warrant attention—but not in the way RFK Jr. proposes
The head of the U.S. Department of Health and Human Services is ignoring decades of research findings.
CDC autism prevalence numbers warrant attention—but not in the way RFK Jr. proposes
The head of the U.S. Department of Health and Human Services is ignoring decades of research findings.
‘These plans are simply not acceptable’: Q&A with Helen Tager-Flusberg
Last week, Tager-Flusberg formed the Coalition of Autism Scientists to push back on the U.S. government’s plans for autism research, as described by Health and Human Services Secretary RFK Jr. The coalition already has 220 members.
‘These plans are simply not acceptable’: Q&A with Helen Tager-Flusberg
Last week, Tager-Flusberg formed the Coalition of Autism Scientists to push back on the U.S. government’s plans for autism research, as described by Health and Human Services Secretary RFK Jr. The coalition already has 220 members.